Nautilus Biotechnology (NAUT) Expected to Post Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Nautilus Biotechnology to post earnings of ($0.1350) per share and revenue of $0.25 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02.

Nautilus Biotechnology Price Performance

Shares of NAUT opened at $1.69 on Monday. The stock has a market cap of $214.77 million, a P/E ratio of -3.67 and a beta of 0.80. The business’s 50 day moving average price is $2.14 and its 200-day moving average price is $2.45. Nautilus Biotechnology has a 52 week low of $0.62 and a 52 week high of $4.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Insider Buying and Selling

In other Nautilus Biotechnology news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the sale, the insider owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. The trade was a 83.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 41.10% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

Large investors have recently modified their holdings of the company. Virtu Financial LLC increased its position in Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after acquiring an additional 3,849 shares during the last quarter. Millennium Management LLC boosted its position in Nautilus Biotechnology by 5.4% in the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after purchasing an additional 52,448 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after purchasing an additional 5,000 shares during the period. Captrust Financial Advisors purchased a new stake in shares of Nautilus Biotechnology during the 4th quarter valued at about $66,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Nautilus Biotechnology during the 4th quarter valued at about $204,000. Institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.